MITO CERV-2试验:西妥昔单抗联合卡铂和紫杉醇治疗晚期或复发宫颈癌的随机II期研究
本研究为随机II期试验,将108例晚期或复发宫颈癌患者随机分为卡铂联合紫杉醇(CP)组53例和CP联合西妥昔单抗(CP-CET)组55例。中位随访23个月,两组中位无事件生存期分别为4.7个月和6.0个月(单侧P=0.43),无显著差异;除皮肤毒性外,严重不良事件发生率无差异。结论认为在未选择的晚期或复发宫颈癌患者中,CP-CET方案并不比单用CP更有效。
要点
- CP-CET组与CP组的中位无事件生存期分别为6.0个月和4.7个月,单侧P=0.43,无显著差异。
- 两组严重不良事件发生率无差异,仅皮肤毒性存在差异。
- 小样本生物标志物分析提示PIK3CA突变可能预测西妥昔单抗耐药。
核心结论
- 在未选择的晚期或复发宫颈癌患者中,西妥昔单抗联合卡铂和紫杉醇方案并不比单用卡铂和紫杉醇更有效。
研究设计与样本
- 随机II期试验,纳入ECOG体能状态评分≤1的晚期或复发宫颈癌患者108例,随机分配至CP组53例或CP-CET组55例。
- CP方案每3周一次共6个周期,CET在开始CP前1周给予400 mg/m2,之后每周给予250 mg/m2,直至疾病进展或出现不可接受的毒性。
- 主要终点为无事件生存期,预设4.5个月预期中位EFS和6.4个月预测中位EFS(HR 0.70),单侧α=0.20,把握度80%,最终意向性治疗分析需89个事件。
主要发现
- 中位随访23个月时,共102例患者发生事件,其中97例进展,61例死亡。
- CP组与CP-CET组的中位无事件生存期分别为4.7个月和6.0个月(单侧P=0.43)。
- CP组与CP-CET组的中位无进展生存期分别为5.2个月和7.6个月(单侧P=0.20)。
- CP组与CP-CET组的中位总生存期分别为17.7个月和17个月(单侧P=0.27)。
- 除皮肤毒性外,两组严重不良事件发生率无差异;小样本生物标志物分析提示PIK3CA突变可能预测西妥昔单抗耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS ≤ 1, were randomized to CP for 6 cycles with or without CET (400 mg/m2 one week before starting CP, then 250 mg/m2 weekly) until disease progression or unacceptable toxicity. Event-free survival (EFS) was the primary endpoint. With a 4.5 months expected median EFS and a 6.4 months predicted EFS (HR 0.70), 0.20 one-tailed α and 80% power, 89 events were required for the final intent-to-treat analysis. RESULTS: 108 patients were assigned to CP (n = 53) or CP-CET (n = 55). Median age was 50, 69% were PS0, 76% had recurrent disease, 91% had distant metastasis and 57% had received previous chemotherapy. After a median follow-up of 23 months, 102 patients had an event, 97 progressed and 61 died. Median EFS was 4.7 and 6.0 months (one-tail P = 0.43), median PFS was 5.2 and 7.6 months (one-tail P = 0.20) and median OS was 17.7 and 17 months (one-tail P = 0.27), with CP and CP-CET, respectively. There was no difference in the occurrence of severe adverse events, except for skin toxicity. Biomarker analysis, in a small subgroup of patients, suggests that PIK3CA mutation might be predictive of CET resistance. CONCLUSION: CP-CET was not more active than CP alone in unselected ARCC patients.
引用
- Pignata S, Scambia G, Lorusso D, et al. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019. PMID: 30979589. doi:10.1016/j.ygyno.2019.03.260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。